SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's stock is trending as investors discuss its potential inclusion in the S&P 500, with the official announcement expected soon. The community is weighing the potential for a short squeeze against the historical trend of stocks dropping after being added to the index. Optimistic traders believe the inclusion, along with upcoming events, will drive the stock higher.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as it joins the S&P 500, sparking excitement and debate about potential short squeezes and future price movement. The community is discussing whether the stock was pumped prior to the announcement and speculating on profit-taking strategies. Some investors express frustration for selling earlier, while others are optimistic about long-term growth.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to its low float, with traders speculating it could be the next stock to experience a significant squeeze. The community is actively discussing its potential for a rapid price increase, drawing comparisons to other low-float stocks that have recently made substantial moves. A recent land sale boosting NAV is also circulating.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is trending as traders discuss the implications of its new ticker symbol and potential connections to blockchain technology through Tzero, drawing comparisons to past meme stock surges like $GME. The community is actively debating whether this is a fresh start or another fleeting rally, and speculating about possible involvement from figures like Ryan Cohen. Some investors believe Overstock's transition to Bed Bath & Beyond, combined with blockchain assets, could drive a significant turnaround.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

aTyr Pharma is trending as investors discuss the potential implications of recent inducement grants and upcoming Phase 3 data, with some speculating about the company's confidence in positive results based on hiring activity. Community perspectives are divided, with bullish arguments emphasizing the potential for a successful outcome and high price targets, while bearish viewpoints focus on past trial data and concerns about short selling strategies. The stock's high short interest and upcoming data readout are contributing to increased volatility and active conversation.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG.X) is trending as the community rallies around the token's $SOL.X reward system for holders, emphasizing its potential for passive income. Despite some volatility and past challenges, the community highlights its resilience and the arrival of new developers, sparking renewed optimism. Discussions also focus on upcoming events and partnerships, contributing to the token's visibility.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue ($KVUE) is trending due to discussions surrounding a report linking Tylenol use during pregnancy to autism, sparking community debate about the validity and potential market impact. Some investors view the dip as a buying opportunity, dismissing the report, while others express concern over potential lawsuits and long-term effects on the company. The broader context includes Kenvue's position as a consumer health company and its relationship with Johnson & Johnson.

Pineapple Financial, Inc. is a Canadian based mortgage technology and brokerage company, which engages in the mortgage brokerage services and technology solutions to Canadian mortgage agents, brokers, sub-brokers, brokerages, and consumers. The company also provides back-office services, together with pre-underwriting support services. The company was founded by Shubha Dasgupta, Kendall Marin, and Charles Andrew Green on October 16, 2015 and is headquartered in North York, Canada.

Pineapple Financial Inc

Pineapple Financial ($PAPL) is trending due to a recently closed $100M private placement and a move into Injective (INJ) tokens, sparking high volatility. The community is buzzing about potential short squeezes and halts, with bulls anticipating further upside and bears cautioning about dilution. Traders are closely watching price action and momentum, with some eyeing new entries while others secure profits.

K9 Finance, a Shibarium-based LSD platform, offers core DeFi services and acts as an official validator. Rewarding $KNINE holders with $BONE for block validation, it aims to drive DeFi adoption via the 'Roundtable of Dogs' DAO, which governs treasury and roadmap decisions.

K9 Finance DAO

K9 Finance DAO ($KNINE.X) is trending as the project continues to build on Shibarium, with the community actively discussing staking $BONE for $knBONE and earning rewards through yield farming. The launch of Bonecrusher v3 and the ongoing retro airdrop are also key catalysts driving interest in the project. K9 Finance aims to enhance DeFi within the Shiba Inu ecosystem, focusing on liquid staking and DAO governance.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is trending as investors discuss its potential for recovery amid S&P 500 removal and debates around solar tax credits. Community talking points include the stock's downtrend, possible bottoming, and sensitivity to interest rate cuts, while some express concerns over policy and market conditions. Despite mixed sentiment, there's optimism about Enphase's technology and long-term prospects in the solar energy sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know

Shares of biopharmaceutical company iTeos Therapeutics, Inc. (ITOS) traded 20% higher on Wednesday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/28/3089457/0/en/iTeos-Therapeutics-Announces-Its-Intention-to-Wind-Down-Operations.html">announced</a> its intent to wind down operations and explore asset sales.iTeos said it decided to wind down operations as part of a review of strategic alternatives aimed at maximizing shareholder value.The Board of Directors now intends to focus on leveraging the company’s cash balance to deliver near-term value to shareholders, including any proceeds from the potential sale of the company’s intellectual property and assets.iTeos ended the first quarter of 2025 with cash and investments of $624.3 million. Last month, the firm had said that it expects its cash balance to provide a runway through 2027.However, earlier this month, iTeos decided to <a href="https://stocktwits.com/news-articles/markets/equity/iteos-gsk-end-collaboration-on-experimental-cancer-therapy/chi8V5tRbZi">terminate</a> its collaboration with British pharmaceutical major GSK Plc for the development of experimental cancer therapy Belrestotug.The two companies were working together assessing the Belrestotug + Dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer.However, data from a Phase 2 study did not show improvements in progression-free survival with the combination compared to Dostarlimab monotherapy, and the companies subsequently decided to terminate the program and end the collaboration.iTeos CEO Michel Detheux had said the company is “truly disappointed” by the trial results and is taking “immediate steps” to preserve capital. &nbsp;On Stocktwits, retail sentiment around ITOS jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_28_at_11_05_44_AM_png_7ce0e324ab.webp" alt="ITOS's Sentiment Meter and Message Volume as of 11:05 a.m. ET on May 28, 2025 | Source: Stocktwits " width="626" height="67"><figcaption>ITOS's Sentiment Meter and Message Volume as of 11:05 a.m. ET on May 28, 2025 | Source: Stocktwits&nbsp;</figcaption></figure>A Stocktwits user expressed optimism about the company’s decision to halt operations.<stembedurl>https://stocktwits.com/BullDriven/message/616043049</stembedurl><a href="https://stocktwits.com/symbol/ITOS">ITOS stock </a>is up approximately 29% this year but down by more than 40% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/candel-therapeutics-gets-rmat-designation-for-prostate-cancer-therapy/ch0om35Rbs0">Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

iTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’

The company decided to wind down operations as part of a review of strategic alternatives aimed at maximizing shareholder value after its collaboration with GSK plc ended. 

Equity

GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug

Shares of iTeos Therapeutics, Inc. (ITOS) rocketed 20% on Tuesday morning after the company announced it has decided to terminate its collaboration with British pharmaceutical major GSK Plc for the development of its experimental cancer therapy Belrestotug.The two companies were working together assessing the Belrestotug + Dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer.However, data from a Phase 2 study did not show improvements in progression-free survival with the combination compared to Dostarlimab monotherapy. Hence, the two companies have decided to end the collaboration and terminate the program.iTeos <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.iteostherapeutics.com/news-releases/news-release-details/iteos-reports-topline-interim-results-galaxies-lung-201-study">also</a> ended new enrollment for a phase 3 trial of the combination.GSK is communicating with investigators, institutional review boards, ethics committees, and health authorities about next steps for the appropriate management of currently enrolled patients, iTeos said.iTeos CEO Michel Detheux said the company is “truly disappointed” by the trial results. The firm is taking “immediate steps” to preserve capital and maximise shareholder value and has engaged TD Cowen to advise on the process.“...given current market conditions and our appreciation of the responsibility to our valued shareholders, we believe the best path forward is to promptly evaluate a full range of strategic alternatives to unlock the value of our assets,” Detheux said, while adding that the company has a strong balance sheet to enable it to pursue opportunities.On Stocktwits, retail sentiment around ITOS jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_13_at_9_51_08_AM_png_54cf65be0f.webp" alt="ITOS's Sentiment Meter and Message Volume as of 9:45 a.m. ET on May 13, 2025 | Source: Stocktwits" width="627" height="62"><figcaption>ITOS's Sentiment Meter and Message Volume as of 9:45 a.m. ET on May 13, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/ITOS">ITOS stock</a> is up by about 5% this year but has declined by about 52% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/vehicle-prices-rose-in-april-after-trump-tariffs/chi8mIbRbZg">Cadillac, Tesla, GMC Vehicles Get More Expensive In April After Trump Tariffs, Shows Data</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish

The two companies worked together to assess the Belrestotug + Dostarlimab doublet in treating a specific type of lung cancer.

iTeos Therapeutics presents preclinical data on EOS-984

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024

WATERTOWN, Mass. and GOSSELIES, Belgium, April 07, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and...

iTeos Therapeutics (ITOS, $13.35) RSI Indicator left the overbought zone on April 01, 2024

This is a signal that ITOS's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Sees Significant Increase in Short Interest

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 2,010,000 shares, an...

iTeos Therapeutics (ITOS, $13.19) RSI Indicator left the overbought zone on March 27, 2024

iTeos Therapeutics (ITOS, $10.81) entered Downtrend as Momentum indicator drops below 0 level on Mar 15, 2024

This indicator may be signaling that ITOS's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Current Price	$10.15
Prev Close	$10.13
Open	$10.14
Dividend Yield	0.00%
50-Day Moving Average	$10.14
Beta	0.96
Avg. Volume	1.56M
PE Ratio	-2.09

52-Week High	$17.63
52-Week Low	$4.80
Market Capitalization	$448.68M
EPS (Annual)	-$3.32
Price to Book	0.91
Revenue Per Employee	$202,312.14
Enterprise Value/EBITDA	N/A

ITOS
ITeos Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ITOS News

ITOS ITeos Therapeutics Inc